Introduction: Laser Interstitial Thermal Therapy (LITT) is a novel technology used to treat primary brain tumors and brain metastases. Previous studies are limited by sample size or to single-center experience. The Laser Ablation of Abnormal Neurological Tissue using Robotic NeuroBlate System (LAANTERN) is an ongoing registry designed to address these limitations. We present the preliminary experience with regard to safety of LITT, as well functional status and survival after LITT for brain tumors.
Methods: The LAANTERN registry is designed to collect baseline, procedural, and follow-up data on patients treated with the NeuroBlate® system. Data collected include baseline demographics, intraprocedural data, adverse events, functional status, and survival.
Results: LAANTERN accrued 127 patients treated with NeuroBlate for primary or metastatic brain tumors. There were 68 (54%) females and 33 (46%) males. Median age was 58 (range 10-80). Median Karnofsky Performance Score (KPS) was 90 (range 40-100) at baseline. Of the treated lesions, 61% were primary and 39% were metastatic tumors. Of the primary tumors, 77% were high-grade gliomas, 13% were low grade gliomas, and 10% were other primary tumors. Greater than 90% volumetric ablation was achieved in 75.9% of cases. Mean post-procedure Intensive Care Unit (ICU) and total hospital stay were 1.69±3.4 days and 3.1±4.7 days, respectively. There were 13 procedure-related adverse events in 11 (8.7%) patients, and 5 events in 4 (3.1%) patients were considered serious. At 3 months, KPS was stable or improved in 58.2% of patients. Neurological exam was unchanged or improved in 80.9% and 73.3% of patients at 1 and 6 months, respectively. At 6 months, 76% of metastases and 81% of primary tumor patients were alive.
Conclusions: Preliminary results from the LAANTERN registry demonstrate an acceptable safety profile and satisfactory functional outcomes of LITT in carefully selected brain tumor patients.
Patient Care: Relatively little clinical data currently exists on the safety, applicability, and functional outcomes and survival following LITT. We hope this work will increase visibility of LITT as a viable treatment option for brain tumor patients. Further, we hope such work will encourage collaboration in registries such as LAANTERN to promote larger studies as the use of LITT for brain tumors becomes more widespread.
Learning Objectives: • To understand the safety profile and most common adverse events after LITT for brain tumors.
• To understand technical and procedural aspects of LITT as reported across multiple institutions.
• To understand outcome measures such as performance status and overall survival in brain tumor patients undergoing LITT.
References: 1. Hawasli AH, Bagade S, Shimony JS, Miller-Thomas M, Leuthardt EC: Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: single-institution series. Neurosurgery 73:1007-1017, 2013
2. Missios S, Bekelis K, Barnett GH: Renaissance of laser interstitial thermal ablation. Neurosurg Focus 38:E13, 2015
3. Mohammadi AM, Hawasli AH, Rodriguez A, Schroeder JL, Laxton AW, Elson P, et al: The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study. Cancer Med 3:971-979, 2014
4. Patel P, Patel NV, Danish SF: Intracranial MR-guided laser-induced thermal therapy: single-center experience with the Visualase thermal therapy system. J Neurosurg 125:853-860, 2016
5. Kamath AA, Friedman DD, Hacker CD, Smyth MD, Limbrick Jr DD, Kim AH, et al: MRI-Guided Interstitial Laser Ablation for Intracranial Lesions: A Large Single-Institution Experience of 133 Cases. Stereotactic and functional neurosurgery 95:417-428, 2017
6. Sloan AE, Ahluwalia MS, Valerio-Pascua J, Manjila S, Torchia MG, Jones SE, et al: Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg 118:1202-1219, 2013